Midazolam

證據等級: L5

預測適應症: 1 個

Midazolam: From Procedural Sedation to Insomnia

One-Sentence Summary

Midazolam is a short-acting benzodiazepine currently positioned for anesthesia induction and procedural sedation rather than as an oral treatment for chronic insomnia. The TxGNN model predicts it may be effective for Insomnia, with 32 clinical trials and 11 publications identified in the search — though only a small, mostly historical subset directly supports this direction. Given a blocking gap in local safety/label data, the current evidence level is L2 and the recommendation is to Hold.

Quick Overview

Item	Content
Original Indication	Not documented in evidence pack (no local marketing authorization on file); available data indicates current clinical use is procedural sedation / anesthesia induction
Predicted New Indication	Insomnia
TxGNN Prediction Score	99.74%
Evidence Level	L2
Taiwan Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed DrugBank mechanism-of-action text is not available for this record. However, the evidence pack's repurposing rationale confirms midazolam is a short-acting benzodiazepine acting at the benzodiazepine binding site of the GABA-A receptor, enhancing GABAergic inhibitory neurotransmission — a pharmacology that is inherently sedative-hypnotic in nature and directly relevant to insomnia treatment.

Clinically, midazolam today is used almost exclusively for anesthesia induction and procedural sedation, not as a chronic oral hypnotic, largely because of its very short half-life, injectable route of administration, controlled-substance status, and dependence/withdrawal risk. The predicted link to insomnia is therefore not a novel mechanistic discovery but reflects a known class effect shared with other benzodiazepine hypnotics (e.g., flurazepam).

This class effect is supported by real historical evidence: several Phase-level RCTs from the 1980s–1990s directly tested oral midazolam in patients with sleep disorders/chronic insomnia and found it effective and generally well tolerated, before its clinical use shifted almost entirely toward procedural sedation. This gives the TxGNN prediction plausible pharmacological and historical grounding, even though it does not represent a new therapeutic hypothesis.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02142595	Phase 4	Completed	111	IV midazolam vs. dexmedetomidine, combined with spinal anesthesia, compared for postoperative sleep quality after TURP; graded most directly relevant (Grade B) trial in the pack.
NCT06407518	NA	Recruiting	280	Preoperative oral midazolam evaluated in patients with sleep disturbance/anxiety undergoing laparoscopic colorectal cancer resection; trial description notes oral midazolam solution is "safe and effective for short-term hypnosis."
NCT07336095	Phase 3	Not yet recruiting	195	Oral melatonin vs. oral midazolam as premedication in children undergoing tonsillectomy, comparing sleep-inducing/anxiolytic effect.
NCT01966315	N/A	Terminated	5	Compared sleep quality/quantity (24-hour polysomnography) and delirium incidence between dexmedetomidine and midazolam in mechanically ventilated ICU patients; terminated early, very small sample.
NCT00826553	Phase 1	Terminated	6	Polysomnographic comparison of sleep stages/total sleep time between α2-agonist (dexmedetomidine) and GABA-agonist (midazolam) sedation; terminated early, very small sample.

Note: 32 trials were retrieved in total; the majority (graded "C" or judged low relevance on review) involve midazolam only as a background sedation agent in unrelated surgical/ICU studies and are not listed here to avoid diluting the evidence table.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
6138072	1983	RCT	British Journal of Clinical Pharmacology	Double-blind study in 30 women with insomnia secondary to neuromuscular disease: midazolam 15 mg and Vesparax both effective hypnotics; midazolam better tolerated with no hangover effect.
6120704	1981	RCT	Arzneimittel-Forschung	Multicenter dose-finding study (75 patients, oral midazolam 10–30 mg) in mild-to-moderate insomnia secondary to musculoskeletal/neuropathic disorders; established optimal dose range.
2121802	1990	RCT	Journal of Clinical Psychopharmacology	Multicenter, randomized, double-blind, parallel-group study of sleep, performance, and plasma levels during 14-day use of flurazepam vs. midazolam in chronic insomnia patients.
2229461	1990	RCT	Journal of Clinical Psychopharmacology	Executive summary of the above 14-day flurazepam vs. midazolam chronic-insomnia study (companion paper; abstract text not available).
17988972	2007	Review	Orvosi Hetilap	General review of insomnia pathogenesis (hyperarousal state) and its relationship to cerebral hypoperfusion; background context, not midazolam-specific.
2883820	1986	Review	Acta Psychiatrica Scandinavica Supplementum	Review of clinical use of hypnotics, discussing benzodiazepine pharmacokinetic/pharmacodynamic differences and rationale for a variety of agents in insomnia subtypes.
36615100	2022	RCT	Journal of Clinical Medicine	Pilot study of lemborexant (not midazolam) for insomnia in high-risk pancreato-biliary patients post-endoscopy; notes benzodiazepines traditionally used for insomnia may worsen delirium risk — relevant safety context.

Safety Considerations

Please refer to the package insert for safety information.

(Key warnings, contraindications, and drug-drug interaction data are not currently available for this record — DDI query returned "not_found," and TFDA package-insert warnings/contraindications are flagged as a Blocking data gap, DG001.)

Conclusion and Next Steps

Decision: Hold

Rationale: Historical Phase-level RCTs (1980s–1990s) show oral midazolam was effective for insomnia/sleep disorders, but this reflects a known benzodiazepine class effect rather than a novel signal, and no recent or large-scale trials directly target chronic insomnia. Critically, TFDA package-insert warnings/contraindications are entirely missing (Blocking gap, DG001), which prevents this candidate from clearing the S1 safety screening stage regardless of efficacy evidence.

To proceed, the following is needed:

TFDA package insert warnings, precautions, and contraindications (DG001, blocking)
DrugBank mechanism-of-action detail (DG002)
Drug-drug interaction data (current DDI query status: not_found)
Assessment of an oral formulation and dosing regimen suitable for chronic insomnia use, given midazolam's short half-life and controlled-substance status
Local marketing authorization pathway analysis, since the drug currently has zero registered licenses
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.